Lapatinib Alternatives Compared
Lapatinib | Verzenio (abemaciclib) | Enhertu (fam-trastuzumab deruxtecan) |
|
---|
Lapatinib | Verzenio (abemaciclib) | Enhertu (fam-trastuzumab deruxtecan) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Lapatinib may also be used for purposes not listed in this medication guide. |
Prescription only
Verzenio (abemaciclib) is a targeted treatment that helps to reduce the growth and spread of cancer cells in the body. It may be used to treat HR+ HER2-, node-positive, early breast cancer at high... View more |
Prescription only
Prescribed for Breast Cancer - Metastatic, Non Small Cell Lung Cancer, Solid Tumors, Breast Cancer, Gastric Cancer. Enhertu may also be used for purposes not listed in this medication guide. |
Related suggestions Breast Cancer
|
|||||||||||||||||||||||
More about Lapatinib | More about Verzenio (abemaciclib) | More about Enhertu (fam-trastuzumab deruxtecan) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Be the first to share your experience with this drug. |
Verzenio has an average rating of 8.2 out of 10 from a total of 25 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 4% reported a negative effect. |
Enhertu has an average rating of 8.0 out of 10 from a total of 24 ratings on Drugs.com. 73% of reviewers reported a positive effect, while 5% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
N/A |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Lapatinib prices |
View all Verzenio prices |
View all Enhertu prices |
||||||||||||||||||||||||
Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Tykerb |
N/A |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
24 hours |
24.8 hours |
136.8 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 624 drugs are known to interact with Lapatinib:
|
A total of 342 drugs are known to interact with Verzenio:
|
A total of 170 drugs are known to interact with Enhertu:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
March 13, 2007 |
September 28, 2017 |
N/A |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.